DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dce41c/malaysia_pharmaceu) has announced the addition of the "Malaysia Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.

Our Malaysia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Malaysia's pharmaceuticals and healthcare industry.

For the Q308 update of the Malaysia Pharmaceuticals & Healthcare report, the author has completely overhauled its drug market forecast model, which has resulted in many new data points through to 2012. Because the tool incorporates five macroeconomic variables, the country’s disease burden and subjective analyst modification, the fundamental change is to the top-line projection. We now expect the value of pharmaceuticals (patented products + generic drugs + over-the-counter medicines) sold in Malaysia to reach US$1.52bn by 2012, which is slightly less than our Q208 forecast of US$1.82bn.

The Malaysian government risks further unpopularity if it goes ahead with plans to encourage individuals to contribute more to public healthcare funds. Because of rising state spending, a leading member of the ruling elite wants people to increase their social responsibility and buy more health insurance. Those that do will receive tax rebates. In line with the regional trend, the author believes that Malaysians will inevitably buy more health insurance over the medium term. However, after the recent protests over steep fuel price hikes, being told to do so will not go down well with electorate.

Due to their strength in innovative products, multinationals control about 70% of the pharmaceutical market, especially in terms of innovative and specialised products. All of the major multinational drug companies are represented in Malaysia, although only a small number have a direct manufacturing presence, largely as a result of restrictive regulatory practices. Companies with significant local production facilities are B Braun Pharmaceuticals, GlaxoSmithKline (GSK), Johnson & Johnson and Ranbaxy. Multinationals, which are primarily represented by the Pharmaceutical Association of Malaysia (PhAMA), are gradually getting involved in the fields of local biotechnology, clinical trials and bio-equivalence studies, illustrating the rising market potential as well as an improvement in operating conditions.

Continuing the regional trend, Malaysian doctors will soon be forced to stop dispensing medicines that they have prescribed. The topic is currently under debate, with all stakeholders – healthcare professionals, patients and the pharmaceutical industry – contributing their opinions on the potential new rules. The author strongly welcomes this separation of roles as there is a clear conflict of interest, but acknowledges that it may not be possible in remote parts of the country.

Key Topics Covered:

"Executive Summary

Malaysia Pharmaceuticals And Healthcare Industry SWOT

Malaysia Political SWOT

Malaysia Economic SWOT

Malaysia Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Asia Pacific Business Environment Rankings For Q308

Limits Of Potential Returns

Risks To Realisation Of Returns

Malaysia – Market Summary

Regulatory Regime

Recent Regulatory Developments

Intellectual Property Regime

Counterfeit Pharmaceuticals

Compulsory Licensing

Free Trade Agreements

Pricing And Reimbursement

Industry Trends And Developments

Epidemiology

Healthcare Sector

Pharmaceutical Sector

Pharmaceutical Demand

Domestic Company Activity

Halal Medicine

Traditional Medicine

Biotechnology And Research

Table: Key Points Of The Malaysian National Biotechnology Policy

Table: The Benefits Of Conducting Biotechnology Research In Malaysia

Recent Biotechnology Developments

Clinical Trials

Medical Devices

Industry Forecast Scenario

Overall Market Forecast

Table: Drug Expenditure And Prescription Market Indicators, 2006-2012 (US$mn unless otherwise stated)

Key Growth Factors – Industry

Table: Malaysia’s Health Expenditure Forecast Indicators

Key Growth Factors – Macroeconomic

Table: Malaysia – Economic Activity

Patented Market Forecast

Table: Malaysia Patented Drug Market Forecast Indicators

Generics Market Forecasts

Table: Malaysia’s Generics Drugs Market Indicators, 2003-2012

OTC Market Forecast

Table: Malaysia’s OTC Market Indicators, 2003-2012 (US$mn unless otherwise stated)

Export/Import Forecasts

Table: Malaysia Pharmaceuticals Exports And Imports Forecasts (US$mn)

Other Healthcare Data Forecasts

Table: Malaysia’s Healthcare Data, 2003-2012

Key Risks To Our Forecast Scenario

Competitive Landscape

Table: Malaysia Pharmaceutical Market, Q406

Table: Leading Firms By 2005 Sales

Company Profiles

Multinational Companies

GlaxoSmithKline (GSK)

Pfizer

Novartis

Merck & Co

Sanofi-Aventis

Ranbaxy Malaysia

Eli Lilly Malaysia

Leading Indigenous Manufacturers

Pharmaniaga

Asia Pharmaceutical Products

Prime Pharmaceutical

Bumimedic

Hovid

Chemical Company of Malaysia (CCM)

Kotra Pharma

YSP Southeast Holding

Our Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

Companies Mentioned:

- GlaxoSmithKline (GSK)

- Pfizer

- Novartis

- Merck & Co

- Sanofi-Aventis

- Ranbaxy Malaysia

- Eli Lilly Malaysia

- Pharmaniaga

- Prime Pharmaceutical

- Bumimedic

- Hovid

- Chemical Company of Malaysia (CCM)

- Kotra Pharma

- YSP Southeast Holding

For more information visit http://www.researchandmarkets.com/research/dce41c/malaysia_pharmaceu.

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716